JIUZHOUTONG Pharmaceutical Group Co., Ltd. (600998)

JIUZHOUTONG Pharmaceutical Group Co., Ltd. (600998)

Jiuzhou Tong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Jiuzhoutong" or "company") is a technology driven full chain pharmaceutical supply chain service enterprise. The company is based on the pharmaceutical circulation, logistics service and medical health and other major health industries. Its main business includes pharmaceutical distribution and supply chain services, general generation total sales and industrial self-production, digital retail Digital logistics and supply chain solutions, medical health and technology value-added services. Since the company was listed on the Shanghai Stock Exchange on November 2, 2010 (abbreviated as Jiuzhou Tong, code: 600998), the company has achieved stable and high-quality development, ranking fourth in China's pharmaceutical and commercial enterprises for many years, leading the private pharmaceutical business enterprises in China, ranking the 100th in fortune (Chinese Version) 500 in 2020.

In 2020, the operating income of kyushutang was RMB 110.866 billion, an increase of 11.42% year-on-year, with net profit attributable to shareholders of the company of 3.075 billion yuan, an increase of 78.10% year-on-year. After non deduction, the net profit attributable to shareholders of the company was 1.866 billion yuan, an increase of 22.33% year-on-year, and net cash flow of operating activities was 3.444 billion yuan, an increase of 24.42% on the same basis. In the first quarter of 2021, the company's operating income was 32.629 billion yuan, an increase of 20.08% year-on-year. As of the end of March 2021, the company has 425 subordinate enterprises and nearly 30000 employees within the scope of consolidated statements.

Since its listing, Jiuzhou Tong has been optimizing its management structure and actively exploring new development models. While ensuring steady growth of business performance, the company has completed the business layout and expansion of all channels and categories, opened the incubation and rapid development of emerging businesses such as general sales business, industrial self-produced business, three-party logistics business and ecological circle investment, and achieved fruitful results in the new mode of traditional business transformation from platform, Internet and digital.

Jiuzhoutong has completed the business layout and expansion of all channels and categories, accumulated a large number of customer resources and business categories, and built a scarce full scene logistics supply chain service platform. In 2020, the company has reached 390000 customers in all channels, including 11000 customers in urban and county public hospitals, 175000 customers of chain and monomer pharmacies, and 168000 customers from grass-roots and private medical institutions; The company has 443900 regulations, including 62300 Chinese and Western medicine regulations, 268600 instruments and 87200 Chinese medicine regulations.

Jiuzhoutong has opened the incubation and rapid development of emerging businesses such as general generation total sales business, and realized the interaction between emerging business and original distribution business platform, and promoted the continuous expansion of market scale and continuous improvement of profitability. In 2020, the company realized total sales and self-produced business revenue of 13.526 billion yuan (including 1239 drug regulations and 320 medical devices sold on the total behalf of the company), and realized the operating income of logistics business of RMB 1.046 billion; In addition, EMC Technology Development Co., Ltd., which relies on the investment of ecological resources, is listed on the gem of Shenzhen Stock Exchange, and the annual net profit return of contribution in 2020 reaches RMB 787million (calculated at fair value).

Jiuzhou Tong continuously explores new models of transformation to platform, Internet and digital, embraces the Internet actively, and continuously increases investment in information technology and logistics technology, so as to better serve upstream and downstream customers and meet the diversified needs of customers; The company has become a technology driven and highly efficient operation of the whole chain pharmaceutical supply chain service enterprise, with 1039 technical developers and system maintenance and redevelopment personnel.

In terms of platform, Jiuzhou Tong has built a full channel "expressway" platform covering chain drugstores, monomer drugstores / clinics, hospitals / grass-roots medical institutions, county level commercial alliance distributors (quasi terminals) and Internet medicine supply chain, and used the platform to operate different kinds of drugs, devices, traditional Chinese medicine, consumer goods and general generation total sales and self-produced products. The company has continuously invested in the construction of the largest infrastructure of the medical supply chain service platform in China, including 137 warehouses and 3.93 million square meters of construction. Among them, the warehouse facilities meeting the GSP standard are 2.57 million square meters and 518 cold storage (covering an area of 44000 square meters and a volume of 100000 cubic meters). The company has built six platforms covering the whole country, including product marketing platform, logistics sharing platform, e-commerce and information operation platform, financial sharing platform, supply chain value-added service platform and ecological investment and financing platform.

In terms of Internet, Jiuzhoutong has built an Internet trading platform and Internet toolkit for providing enabling services for customers from the perspective of pharmaceutical distribution and retail. In 2020, the sales revenue of the company's B2B "new distribution" of medicine through the Internet and digital platform reached 9.354 billion yuan, of which, the company's pharmaceutical B2B e-commerce platform realized sales of 5.518 billion yuan, and the app platform of Zhiyao Tong gathered 150000 business personnel from manufacturers, which led the company to realize the sales of 3.836 billion yuan, including the pharmaceutical supply chain business provided to the Internet enterprise platform, During the reporting period, the company's self-supporting e-commerce platform achieved sales of 12.7 billion yuan, and has become the largest self-supporting medicine B2B e-commerce platform in China. The company launched Internet service tools such as "intelligent medicine cloud", "smart Drugstore", "medical and health assistant", enabling customers such as more than 200000 grade hospitals, pharmacies and grass-roots medical institutions offline to provide backstage service support for the medical supply chain and internet medical prescription.

In terms of digitization, Jiuzhoutong is a few modern digital medicine circulation enterprises with national unified ERP system and master data management system independently researched and developed. The company's digital system can not only improve the management level and operation efficiency, but also provide value-added services to the outside, and also support efficient and safe logistics supply chain services. In October, 2020, the company's self-designed "Shenzhou No. 1" modern intelligent medicine logistics center (version 3.0) was successfully put into operation in Zhengzhou, Henan Province. This is not only the modern pharmaceutical logistics center with the most innovative technology application, representing the highest level of Jiuzhou Tong's own pharmaceutical logistics, but also has a leading position in the industry.

In 2020, in response to the impact of COVID-19, Kyushu made full use of the pharmaceutical supply chain service capabilities of all channels, all categories and the whole scene, and actively participated in the "anti epidemic and supply guarantee" action, becoming the largest supplier of anti epidemic materials in Hubei. In the outbreak sniping war, the company was ordered to rescue Wuhan red cross to manage anti epidemic materials. The company quickly straightened out the distribution process of donated materials by using the "Jiuzhou cloud warehouse" management system and accumulated big data platform, and delivered the donated materials to the designated units in the shortest time, which strongly supported the fight against epidemic; The nine letter novel coronavirus pneumonia group, commissioned by the "people's hero" Zhang Boli, has made over 400 tons of Chinese herbal medicine for the designated hospitals, shelter hospitals and isolation points, which has made outstanding contributions to the treatment of new crown pneumonia by Chinese medicine. It has become a hot spot in 2020, and has received wide acclaim from the government and the society. In recent years, the company has also won many honorary titles, such as "national 5A logistics enterprise", "Hubei most influential private enterprise", "national contract abiding and trustworthy enterprise", "excellent enterprise with excellent sense of social responsibility in China", "top 100 Hubei enterprise", "top 100 service industry of private enterprises in China" and "top 500 Chinese enterprises".

In 2021, Kyushu will take precautions against COVID-19 as one of the core tasks, actively cooperate with the important deployment of national epidemic prevention and control, give full play to the advantages of cold chain logistics distribution and distribution, storage, system management and operation, and do a good job in vaccine cold chain distribution service. 2021 is the key year for Jiuzhoutong to implement and implement the group's three-year strategic plan. The company will continue to promote the transformation and upgrading of the company, utilize the advantages of digitalization, platform and Internet, strengthen the core business advantages of all channels and categories, continue to optimize business structure and promote the proportion of terminal pure sales mainly dominated by large terminal channels; While consolidating and developing the channels of hospitals, retail pharmacies and grass-roots medical institutions, the company unswervingly expanded the "WanDian alliance" plan, and realized the connection with the store communication system of 10000 pharmacies in the year, and achieved 5000 franchised pharmacies; The company will continue to strengthen the service capacity of the supply chain, and according to the new business form changes, the existing B2B warehouse distribution service system will be transformed into the BC warehouse distribution integrated integrated service system, and the 137 warehouses distributed in the country will be systematically upgraded in a planned and step-by-step manner, and a supply chain system that can serve both end-b users will be fully built, It can also serve the supply chain system of C-end users; The company will continue to strengthen the construction of the marketing system of general sales products and self-produced products, and continuously enhance the service ability for upstream and downstream customers, and create greater value for customers.

The big health industry is the sunrise industry forever. The company will continue to implement the enterprise mission of "caring for the health of the people, often surprise customers, and building a win-win platform for cooperation", seize the policy opportunities of the state to vigorously develop the health industry, continue to promote the company to leap and upgrade from traditional enterprises to platform, digital and Internet-based innovation enterprises, and achieve and exceed the three-year strategic planning objectives of the company, We will maintain the company's sustained and stable high-quality development and strive to be the most professional and large health service platform in China.

>>ATOP ring oil pump jack for sale electrical submersible pump manufacturers